Stefano Rusconi to HIV Infections
This is a "connection" page, showing publications Stefano Rusconi has written about HIV Infections.
Connection Strength
1.008
-
Clinical pharmacology in HIV cure research - what impact have we seen? Expert Rev Clin Pharmacol. 2019 Jan; 12(1):17-29.
Score: 0.123
-
Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective. New Microbiol. 2017 Apr; 40(2):75-79.
Score: 0.109
-
Research news in clinical context. Sex Transm Infect. 2020 Dec; 96(8):553-554.
Score: 0.035
-
Factors associated with hospital admission for COVID-19 in HIV patients. AIDS. 2020 11 01; 34(13):1983-1985.
Score: 0.035
-
Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res. 2020 07; 157:104826.
Score: 0.034
-
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. J Antimicrob Chemother. 2020 01 01; 75(1):194-199.
Score: 0.033
-
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019 Dec; 54(6):728-734.
Score: 0.032
-
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019 05 01; 74(5):1363-1367.
Score: 0.031
-
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials. 2018 12; 19(6):242-248.
Score: 0.031
-
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. BMC Infect Dis. 2018 Nov 12; 18(1):556.
Score: 0.030
-
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
Score: 0.030
-
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Med. 2018 05 29; 16(1):79.
Score: 0.029
-
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. AIDS Rev. 2018 Apr-Jun; 20(2):75-82.
Score: 0.029
-
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial. New Microbiol. 2018 Apr; 41(2):106-111.
Score: 0.029
-
Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. Ann Pharmacother. 2018 08; 52(8):740-746.
Score: 0.029
-
Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience. J Women Aging. 2019 Mar-Apr; 31(2):176-188.
Score: 0.029
-
Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. PLoS One. 2017; 12(12):e0189045.
Score: 0.029
-
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. AIDS Patient Care STDS. 2017 Dec; 31(12):487-494.
Score: 0.028
-
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One. 2017; 12(11):e0187393.
Score: 0.028
-
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017; 12(10):e0186638.
Score: 0.028
-
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data. BMC Infect Dis. 2017 09 30; 17(1):658.
Score: 0.028
-
Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017 08 09; 17(1):551.
Score: 0.028
-
Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy. J Acquir Immune Defic Syndr. 2017 07 01; 75(3):315-321.
Score: 0.028
-
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One. 2017; 12(6):e0179254.
Score: 0.028
-
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA =50 cp/mL. Infection. 2017 Aug; 45(4):521-528.
Score: 0.027
-
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
Score: 0.027
-
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017 01 28; 31(3):455-457.
Score: 0.027
-
Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. New Microbiol. 2017 Apr; 40(2):139-142.
Score: 0.027
-
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017 01 28; 31(3):457-459.
Score: 0.007